Biomarin Pharmaceutical Inc (BMRN)
Return on equity (ROE)
| Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net income (ttm) | US$ in thousands | 426,859 | 322,291 | 256,589 | 205,455 | 167,645 | 147,021 | 99,991 | 71,615 | 141,561 | 83,912 | 54,070 | 39,347 | -64,080 | 10,846 | 832,143 | 790,019 | 854,029 | 852,025 | 122,258 | 114,006 |
| Total stockholders’ equity | US$ in thousands | 5,657,990 | 5,413,400 | 5,286,300 | 5,073,820 | 4,951,550 | 4,896,900 | 4,782,830 | 4,659,040 | 4,603,160 | 4,568,510 | 4,499,740 | 4,386,240 | 4,265,670 | 4,261,080 | 4,236,500 | 4,162,010 | 4,100,930 | 4,053,890 | 3,236,680 | 3,239,960 |
| ROE | 7.54% | 5.95% | 4.85% | 4.05% | 3.39% | 3.00% | 2.09% | 1.54% | 3.08% | 1.84% | 1.20% | 0.90% | -1.50% | 0.25% | 19.64% | 18.98% | 20.83% | 21.02% | 3.78% | 3.52% |
December 31, 2024 calculation
ROE = Net income (ttm) ÷ Total stockholders’ equity
= $426,859K ÷ $5,657,990K
= 7.54%
Biomarin Pharmaceutical Inc's return on equity (ROE) has shown fluctuations over the period from March 31, 2020, to December 31, 2024. The ROE started at a relatively low level of 3.52% in March 2020 and saw a slight increase to 3.78% by June 2020. Subsequently, there was a significant rise in ROE to 21.02% by September 2020 and remained above 20% until March 2021, reflecting strong profitability relative to shareholders' equity during this period.
However, from September 2021 to December 2021, there was a sharp decline in ROE, dropping to 0.25% and turning negative to -1.50%, indicating potential operational challenges or inefficiencies impacting the company's bottom line. The ROE recovered to 3.08% by December 2022 but remained relatively low in comparison to the peak levels observed earlier.
From March 2023 onwards, the ROE showed a gradual improvement, reaching 7.54% by December 2024. This trend suggests that Biomarin Pharmaceutical Inc's profitability relative to shareholders' investment has been on an upward trajectory, indicating a potential turnaround in financial performance.
Overall, Biomarin Pharmaceutical Inc's ROE has demonstrated variability over the analyzed period, with periods of strong profitability followed by challenges. Monitoring the ROE trend can provide insights into the company's ability to generate returns for its shareholders and its overall financial health.
Peer comparison
Dec 31, 2024